Почетна › Акутна миелоидна леукемија › Мичиген

Клинички испитувања за Акутна миелоидна леукемија во Мичиген

24 студии за Акутна миелоидна леукемија бараат учесници на локации во Мичиген.

Градови во Мичиген

Официјален текст на студијата (англиски)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
и уште 3

Се регрутираФаза 2

Возраст 60 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
и уште 68

Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери

Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
и уште 6

Се регрутираФаза 2

Возраст од 18 до 59 · Сите полови · Ажурирано 28.9.2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Henry Ford Health System, Detroit
Trinity Health Michigan Heart - Ann Arbor Campus, Ypsilanti

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
и уште 14

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

C S Mott Children's Hospital, Ann Arbor

Се регрутираФаза 1

До возраст 21 · Сите полови · Ажурирано 23.9.2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
и уште 6

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
и уште 11

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
и уште 9

Се регрутираФаза 2

Возраст од 18 до 59 · Сите полови · Ажурирано 22.9.2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo
и уште 1

Се регрутираФаза 3

6 Months – 21 Years · Сите полови · Ажурирано 17.9.2026 · NCT04293562

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

START Midwest, Grand Rapids

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo

Се регрутираФаза 3

Возраст од 1 до 25 · Сите полови · Ажурирано 4.9.2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
и уште 2

Се регрутираФаза 1/2

До возраст 22 · Сите полови · Ажурирано 25.8.2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

C.S. Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit

Се регрутираФаза 3

29 Days – 21 Years · Сите полови · Ажурирано 24.8.2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of Michigan, Ann Arbor
Wayne State University School of Medicine, Detroit

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 20.8.2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Karmanos Cancer Institute, Detroit
Henry Ford Cancer Institute, Detroit

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 20.8.2026 · NCT06001788

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

START Midwest, Grand Rapids

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 7.8.2026 · NCT07751991

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Henry Ford Cancer Institute, Detroit

Се регрутираФаза 3

Возраст од 18 до 75 · Сите полови · Ажурирано 17.7.2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

University of Michigan, Ann Arbor
Children's Hospital of Michigan, Detroit
Henry Ford Health System, Detroit
и уште 2

Се регрутираНабљудувачка студија

Сите возрасти · Сите полови · Ажурирано 6.7.2026 · NCT01351545

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

University of Michigan, Ann Arbor

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 15.6.2026 · NCT05768932

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

West Michigan Cancer Center, Kalamazoo

Се регрутираНабљудувачка студија

Возраст 18 и постари · Сите полови · Ажурирано 7.5.2026 · NCT02269592

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Karmanos Cancer Institute, Detroit

Се регрутираФаза 2

Возраст од 18 до 66 · Сите полови · Ажурирано 17.3.2026 · NCT06859424

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

University of Michigan Comprehensive Cancer Center, Ann Arbor
Karmanos Cancer Institute, Detroit

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 13.3.2026 · NCT05735184

HPC Offered for PRESERVE Expansion

Henry Ford Health, Detroit

Се регрутираНабљудувачка студија

Возраст од 12 до 80 · Сите полови · Ажурирано 28.8.2025 · NCT07145411

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.